Month: September 2023

Kimberley Kates – CEO Big Screen Entertainment GroupKimberley Kates and the Big Screen team presents at the Emerging Growth ConferenceLOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) — Big Screen Entertainment Group (OTC:BSEG) is inviting individual and institutional investors, advisors and analysts to attend its real-time, interactive presentation at the next Emerging Growth Conference. Executives of the dynamic media company will be presenting an update on Big Screen’s latest projects at the September 7, 2023, live online event from 2:55 EST. Existing shareholders and the investment community are to have the opportunity to hear from the Los Angeles based public company’s CEO, Kimberley Kates, COO, Sandro Monetti and President of Development, Catherine Taylor. Please submit your questions in advance to Questions@EmergingGrowth.com...

/NOT FOR DISTRIBUTION TO U.S. WIRE SERVICESOR FOR DISSEMINATION IN THE U.S./ TORONTO, Sept. 07, 2023 (GLOBE NEWSWIRE) — Urbana Corporation (TSX & CSE: URB & URB.A) Urbana Corporation announces that today, it has revalued its investment in Blue Ocean Technologies LLC based on a recent equity raise transaction. This revaluation has the impact of increasing Urbana’s net assets per share (“NAPS”) by approximately $0.93 (or approximately 11.9%) from its last published NAPS as at September 1, 2023. Urbana publishes every Tuesday its NAPS as at the closing on the previous Friday. This revaluation will be reflected in our next weekly NAPS calculation to be published on next Tuesday, September 12. PDF versions of the documents are available at www.urbanacorp.com and at www.sedar.com. For further information contact:Elizabeth NaumovskiInvestor...

Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport syndrome with nonsense mutations Rebound in average UPCR 3-months post treatment provides further evidence that proteinuria remission in one out of three patients was drug related All 3 Alport patients (100% response rate) treated with ELX-02 had biopsy confirmed disease regression, suggesting clinical benefit likely with longer treatment duration Significant strategic interest in ZKN-013 following FDA approval to start Phase 1 single ascending dose (SAD) trial WATERTOWN, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today provided an update on the continued advancement of ELX-02 for the...

Five upcoming scientific presentations will add to the body of evidence supporting the advancement of LX9211 into late-stage development Phase 2b dose optimization study planning underway, with initiation of dosing expected before the end of 2023, and extension to run in parallel with next-stage Phase 3 studies THE WOODLANDS, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a series of five upcoming scientific presentations on its investigational drug LX9211, which is being evaluated in clinical trials for the treatment of diabetic peripheral neuropathic pain (DPNP). Data will be shared through four oral presentations and one poster presentation at various global Congresses. Presentations are as follows:NeuPSIG 2023 International Congress on Neuropathic Pain, Sept. 7-9; Lisbon,...

MILWAUKEE, Sept. 07, 2023 (GLOBE NEWSWIRE) — Twin Disc, Inc. (NASDAQ: TWIN), today announced that Chief Executive Officer John Batten and Chief Financial Officer Jeff Knutson are presenting at the Sidoti September 2023 Virtual Small-Cap Conference on Thursday, September 21 at 12:00 pm Central. In conjunction with the event, Twin Disc executives will be available to participate in one-on-one meetings with investors registered to attend the conference. The event will be streamed live via a webcast available on the Investor Presentations section of Twin Disc’s website at https://ir.twindisc.com. About Twin DiscTwin Disc, Inc. designs, manufactures and sells marine and heavy-duty off-highway power transmission equipment. Products offered include marine transmissions, azimuth drives, surface drives, propellers and boat management systems,...

IRVING, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) — Exela Technologies, Inc. (“Exela” or “the Company”) (NASDAQ: XELA, XELAP), a leader in business processing automation (“BPA”) announced today that the Company signed a new customer for its Marketing Execution solution (“XME”). Exela’s customer, a large regional healthcare provider, was using multiple vendors for print, promotional products and branded apparel leading to inefficiencies and escalating costs. The customer also experienced operational issues with reporting, inventory control, and invoicing. Exela’s XME solution will provide real-time reporting, inventory management, and print-on-demand enabling the elimination of over-inventoried items, reducing the cost of carry on their books and eliminating obsolete materials that needed to be discarded. The TCV of the contract is...

Table 1Table 1Chart 1Chart 1Chart 2Chart 2Table 2Table 2All study objectives were met, demonstrating safety across dose groups and confirming efficacy and durability at the selected doses against placebo (lidocaine) and active control (steroid). All RTX doses (7.5 to 20 µg) were well-tolerated, with few severe or serious adverse events (AEs). The majority of reported AEs related to pain post-administration and resolved within hours following treatment. Very few severe AEs were reported across groups (including placebo) with no dose correlation. RTX post-injection administration pain was easily controlled. RTX 20mcg dose outperformed all other dose groups (including the approved drug for this indication (intra-articular corticosteroids)) for efficacy and durability at and beyond 26 weeks post-treatment....